Intellipharmaceutics International Inc. (IPCI)

[AngeloFoca]

Opana ER brought in $158 million in sales last year for Endo,

No reason why Rexista can't bring in at least that much in about 2 years.

“Do the benefits of reformulated Opana ER continue to outweigh its risks.” That would be a big loss for Endo, as Opana ER is the company’s most profitable pain management drug. Poor Endo... maybe there's still a chance to nab Rexista???

William Blair analyst Tim Lugo believes that the likelihood of Opana ER being pulled off the market has increased

We believe that gross margins for Opana ER are in the range of branded products (>80%) I put that in there for those who insist on posting that margin on Rexista is in the 20% range.